Blog
RSS FeedPosted by Michael Wonder on 15 Nov 2018
Lowering the price of new drugs comes with too high a cost — Canadians' health
14 November 2018 - Ottawa wants to apply new price regulations, which will only cut manufacturer profits and deter the introduction ...
Posted by Michael Wonder on 15 Nov 2018
'Death sentence': One-in-a-million rare cancers get the 'sorting hat' treatment
13 November 2018 - For people with the rarest of cancers, the hope of survival or an effective treatment can ...
Posted by Michael Wonder on 14 Nov 2018
My Health Record opt-out deadline extended after system crash
14 November 2018 - Federal Health Minister Greg Hunt has agreed to extend the My Health Record opt-out deadline, after ...
Posted by Michael Wonder on 13 Nov 2018
Canada's HTA agency releases report on international biosimilar policies
8 November 2018 - The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health ...
Posted by Michael Wonder on 13 Nov 2018
ICR responds to NICE decision on olaparib for women with advanced ovarian cancer
9 November 2018 - NICE has announced today its decision not to recommend olaparib for women with advanced ovarian cancer ...
Posted by Michael Wonder on 12 Nov 2018
PBAC shows no propensity to support Amgen's innovative method of analysis
12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...
Posted by Michael Wonder on 12 Nov 2018
Biosimilar drugs promise to slash health care costs in rich countries
8 November 2018 - The world's top-selling drug now faces biosimilars that are 80% cheaper. ...
Posted by Michael Wonder on 12 Nov 2018
Billion dollar drug company wants to be 'reimbursed' with taxpayer funding
11 November 2018 - An American drug company which hopes to treat New Zealand children for a rare genetic disorder ...
Posted by Michael Wonder on 12 Nov 2018
SMC - November 2018 decisions
12 November 2018 - A medicine used to treat a rare cancer which occurs predominantly in very young children has ...
Posted by Michael Wonder on 12 Nov 2018
Availability of Orkambi on the NHS
9 November 2018 - The Health and Social Care Committee has formally requested documents from Vertex Pharmaceuticals, NHS England and ...
Posted by Michael Wonder on 11 Nov 2018
Novartis' erenumab proving to be a headache for the PBAC
12 November 2018 - Record number of consumer comments; place in clinical therapy unclear. ...
Posted by Michael Wonder on 10 Nov 2018
Public Summary Documents - April 2018 PBAC meeting
9 November 2018 - The Public Summary Documents from the April 2018 PBAC meeting are now available. ...
Posted by Michael Wonder on 10 Nov 2018
Public Summary Documents - July 2018 PBAC meeting
9 November 2018 - The second tranche of Public Summary Documents from the July 2018 PBAC meeting (first time rejections and ...
Posted by Michael Wonder on 10 Nov 2018
NICE says no to expanding use of AstraZeneca's’ Lynparza
9 November 2018 - NICE has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian ...
Posted by Michael Wonder on 09 Nov 2018
Lenvima backed for NHS use to treat liver cancer
9 November 2018 - NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and ...